Prevalence of sarcopenia under different diagnostic criteria and the changes in muscle mass, muscle strength, and physical function with age in Chinese old adults
At present, there are several diagnostic criteria of sarcopenia were used in China, and the diagnostic criteria were not unified. This study aims to investigate the consistency between the latest sarcopenia diagnostic criteria Asian Working Group for Sarcopenia(AWGS 2019) and other common diagnostic criteria. The changes of muscle mass, muscle strength and physical function with age and their effects on the diagnosis of sarcopenia were also analyzed.
Methods
A total of 1009 men aged ≥60 years were enrolled from multiple communities. Skeletal muscle mass index, grip strength and 6 m gait speed were measured. The consistency of AWGS 2019 with other diagnostic criteria was analyzed and the trends of these three indicators were observed. The differences of muscle mass, muscle strength and function among different diagnostic criteria and age groups were evaluated. In addition, the change trends of these three indicators with age were observed.
Results
According to AWGS 2019 diagnostic criteria, the incidence of sarcopenia in male aged 60–69 years, 70–79 years and over 80 years was 1.5%, 9.6% and 33.1%, respectively. AWGS 2019 was highly consistent with other diagnostic criteria (Kappa = 0.66–0.80, P < 0.01), except the Foundation for the National Institutes of Health(FNIH) (Kappa = 0.32, P < 0.01). When AWGSA2019 diagnostic criteria are applied, the prevalence of decreased muscle strength (39.1%) and physical function (46.4%) was significantly higher than that of low muscle mass (35.9%) in the men over 80 years old. Muscle strength (P < 0.01) and function (P < 0.01) decreased at the same rate with age, both of which were more significant than muscle mass (P < 0.01).
Conclusion
AWGS 2019 was highly consistent with other criteria. Maintaining muscle mass should be the focus of attention before age 80, while improving muscle strength and function should be focused after age 80 to prevent disability.
Hinweise
Mengyu Cao and Junsong Lian contributed equally to this work.
Xiaolei Qi, Guogang Xu and Nan Peng share senior authorship.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ASM
Appendicular Skeletal Muscle Mass
SMI
Skeletal Muscle Mass Index
AWGS
Asian Working Group for Sarcopenia
EWGSOP
European Working Group on Sarcopenia in Older People
IWGS
The International Working Group on Sarcopenia
FNIH
The Foundation for the National Institutes of Health
PPA
Positive Predictive Value
NPA
Negative Predictive Value
LMM
Low Muscle Mass
LMS
Low Muscle Strength
LPF
Low Physical Function
MM
Muscle Mass
MS
Muscle Strength
PF
Physical Function
Background
Aging of population is a serious challenge in China. The seventh national census show that the number of people aged ≥60 accounts for 18.7% of the total population, and the number of disabled people reaches 52.71 million [1]. According to a demographic study by Peking University [2], it is estimated that by 2030, there will be more than 77 million disabled old adults in China with a disability period of 7.44 years, and by 2050, the proportion of disabled people will increase to more than 70% if without prevention and control measures. Sarcopenia is generally defined as age-associated loss of skeletal muscle mass accompanied by decreased muscle strength and/or decreased body function, is one of the major concerns in the old adults in recent years. Sarcopenia significantly increases the risk of fall, prolonged bed rest, developing chronic disease, re-hospitalization, physical disability and even death in the elder population [3, 4]. Therefore, early diagnosis and prevention of sarcopenia have attracted much attention.
The diagnostic criteria of sarcopenia are not uniform, and the diagnostic procedures of several sarcopenia working groups are constantly being updated. In recent years, the European and Asian sarcopenia working groups have updated the diagnostic criteria, but there is a lack of large-scale epidemiological studies in China that apply the latest diagnostic criteria. In addition, the changes of muscle mass, muscle strength and physical function, which are important diagnostic indicators of sarcopenia closely related to aging, are still barely known.
Anzeige
Therefore, this study focused on the old adults in the community and compared the efficacy of the latest diagnostic criteria of sarcopenia. The changes of muscle mass, muscle strength and function with age were analyzed.
Methods
Study participants
This study initially screened 1446 old adults from multiple communities in different districts (including Haidian District, Chaoyang District, Fengtai District, Dongcheng District and Xicheng District) of Beijing, China from April to July 2019. The primary community health centers affiliated with the PLA General Hospital invited people aged 60 years from these communities to participate in the study. Because the characteristics of the population lead to the low number of women recruited, and previous research have found that the prevalence of sarcopenia varies greatly by sex. Therefore, to avoid gender differences in the overall prevalence of sarcopenia, we excluded female and included only male in the study.
Inclusion criteria were: 1) Male subjects aged ≥60 years, 2) Subjects had the ability to complete various test projects, 3) Subjects who voluntarily participated in and cooperated with the research. Exclusion criteria were: 1) Subjects with severe bone, joint or muscle diseases with pain and limited activity, 2) Subjects who could not stand by themselves, 3) Subjects with heart, lung or other important organ diseases in acute or terminal stage, 4) Subjects with severe cognitive or communication disorders, or surgical history within 5 or 6 months, 6) Subjects with pacemaker implantation or other metal implantation,7) Subjects being resident in 24-hour care institutions.
According to the inclusion and exclusion criteria, a total of 437 people were excluded. Female subjects (76), subjects under 60 years old (253), and subjects who did not meet the inclusion criteria (108) were excluded. Therefore, a total of 1009 males were finally included in this study. Their age ranged from 60 to 98 years old, with an average age of 73.9 ± 8.65 years old and a median age of 73 years old. The study complied to the criterion of the Declaration of Helsinki. The research proposal was authorized by the Ethics Committee and the Institutional Review Committee of Hospital (Approval Number: S2019–140-01). Each patient was told about the study and signed the Informed Consent.
Anzeige
Measurements of sarcopenia
Muscle mass
Skeletal muscle mass was determined with body composition analyzer (Model Inbody770, Seoul Bodi Co., LTD., South Korea). Subjects should fast as much as possible and metal objects such as necklaces and watches should be removed. Bioelectrical impedance analysis was used to measure appendicular skeletal muscle mass (ASM) in extremities [5]. The skeletal muscle mass index (SMI) was calculated with formula: SMI = ASM/ height2.
Muscle strength
The handgrip strength test was performed using a hand-held electronic grip meter (JAMAR, Sammons Preston). The subjects were instructed to press hard for 3 to 5 seconds until the number stops rising [6]. The handgrip strength test was conducted for 3 times and the maximum value of the dominant hand was recorded. Subjects rested for 1 ~ 2 min after each measurement.
Physical function
For the gait speed test, 10 m measuring space was reserved and the subjects were instructed to walk the whole distance at their daily pace. Timing started at 2 m and ended at 8 m [7]. The walking time of 6 m was measured, and the gait speed was calculated. Walking was permitted while using a walking aid such as a stick or frame.
Diagnostic criteria
In this study, 6 different diagnostic criteria that are currently most widely used were selected to diagnose sarcopenia, including the Asian Working Group for Sarcopenia (AWGS2014 [8] and AWGS2019 [9]), European Working Group on Sarcopenia in Older People (EWGSOP1 [10] and EWGSOP2 [11]), the International Working Group on Sarcopenia [12] (IWGS) and the Foundation for the National Institutes of Health [13] (FNIH). The details of these diagnostic criteria are shown in Table 1.
Table 1
Different diagnostic criteria of sarcopeniaa
①Muscle mass (SMI)
②Muscle strength (Handgrip strength)
③Physical function (Gait speed)
Diagnosis
AWGS2019
< 7.0 kg/m2
< 28 kg
< 1 m/s
① + ②/① + ③
EWGSOP2
< 7.0 kg/m2
< 27 kg
≤0.8 m/s
① + ②
AWGS 2014
< 7.0 kg/m2
< 26 kg
≤0.8 m/s
① + ②/① + ③
EWGSOP1
< 7.23 kg/m2
< 30 kg
≤0.8 m/s
① + ②/① + ③
IWGS
< 7.23 kg/m2
–
< 1 m/s
① + ③
FNIH
ALMBMI < 0.789
< 26 kg
≤0.8 m/s
① + ② + ③
SMI skeletal muscle mass index, AWGS Asian Working Group for Sarcopenia, EWGSOP European Working Group on Sarcopenia in Older People, IWGS the International Working Group on Sarcopenia, FNIH the Foundation for the National Institutes of Health
aThe cut-off values in the above diagnostic criteria were all males. The cut-off values for females were not listed separately
Statistical methods
Statistical analysis was conducted using SPSS 17.0(IBM, Chicago, IL). The consistency of AWGS2019 with other diagnostic criteria was analyzed by Kappa value, positive predictive value (PPA), and negative predictive value (NPA). Group analysis of low muscle mass (LMM), low muscle strength (LMS) and low physical function (LPF) was performed according to different diagnostic criteria and ages, and the differences among groups were detected by Chi-square test. Linear regression analysis was used to assess and compare age-related changes in muscle mass, muscle strength, and physical function. In order to compare the reduction of the age-related indicators in different age groups, all variables were divided by the standard value (cut-off value) and standardized [14]. A P-value < 0.05 was considered statistically significant.
Results
Clinical characteristics of participants
The enrolled participants were divided into 60–69 years old group (n = 396), 70–79 years old group (n = 365) and over 80 years old group (n = 248). The statistical results of various measurement indexes (age, height, weight, SMI, handgrip strength and gait speed) in all age groups are shown in Table 2. The average SMI, handgrip strength and gait speed of the total old adults were respectively (7.59 ± 0.69) kg/m2, (36.47 ± 8.01) kg and (1.26 ± 0.27) m/s. With the increase of age, SMI, handgrip strength and gait speed of the old adults showed varying degrees of decline.
Table 2
Baseline characteristics of the subjects (N = 1009)
60–69 years (n = 396)
70–79 years (n = 365)
Over 80 years (n = 248)
Total (N = 1009)
Age (year)
65.5 ± 2.49
74.7 ± 2.70
86.0 ± 4.69
73.9 ± 8.65
Height (cm)
172.60 ± 5.19
170.84 ± 4.97
168.46 ± 5.45
170.9 ± 5.42
Weight (kg)
74.70 ± 9.60
72.45 ± 9.28
69.07 ± 9.90
72.5 ± 9.80
SMI (kg/m2)
7.82 ± 0.59
7.60 ± 0.64
7.20 ± 0.73
7.59 ± 0.69
Handgrip strength (kg)
40.87 ± 6.65
36.43 ± 6.60
29.51 ± 6.88
36.47 ± 8.01
Gait speed(m/s)
1.41 ± 0.20
1.27 ± 0.21
1.01 ± 0.28
1.26 ± 0.27
FTCST(s)
9.29 ± 2.67
10.70 ± 3.13
13.94 ± 4.56
10.94 ± 3.83
Balance test(s)
side by side stand
10.00 ± 0.00
10.00 ± 0.00
9.8 ± 1.17
9.9 ± 0.95
semi-tandem stand
9.94 ± 0.43
9.90 ± 0.57
9.5 ± 1.68
9.81 ± 0.95
tandem stand
9.48 ± 2.82
9.53 ± 1.55
8.32 ± 2.65
9.21 ± 2.44
SPPB (score)
11.53 ± 0.83
11.23 ± 1.07
9.68 ± 12.61
10.97 ± 1.53
SMI skeletal muscle mass index, FTCST five-time chair stand test, SPPB Short Physical Performance Battery
The incidence of sarcopenia under different diagnostic criteria
The old adults were diagnosed with sarcopenia based on different criteria, and stratified statistics were carried out according to age. According to the diagnostic criteria of AWGS2019, AWGS 2014, EWGSOP2, EWGSOP1, IWGS and FNIH, the number of cases diagnosed with sarcopenia were 87 cases (8.6%), 60 cases (5.9%), 54 cases (5.4%), 123 cases (12.2%), 87 cases (8.6%) and 23 cases (2.3%), respectively. The highest number was observed under EWGSOP1 criteria and the lowest number was found under FNIH criteria. The prevalence of sarcopenia increased with age, especially among those over 80 years old (Fig. 1). The prevalence of sarcopenia was 0–1.5% in 60–69 years old group, 0–9.6% in 70–79 years old group and 9.3–33.1% in over 80 years old group. In addition, there was a remarkable increase in the incidence of sarcopenia diagnosed by IWGS criteria, second only to EWGSOP1 criteria, in those over 80.
Fig. 1
Comparison of the prevalence of sarcopenia in different age groups under different diagnostic criteria. AWGS: Asian Working Group for Sarcopenia; EWGSOP: European Working Group on Sarcopenia in Older People; IWGS: the International Working Group on Sarcopenia; FNIH: the Foundation for the National Institutes of Health
×
Consistency analysis between AWGS 2019 and other diagnostic criteria
The AWGS2019 criteria had a wide range of PPA compared with the other five diagnostic criteria, ranging from 21.8% for FNIH to 83.9% for EWGSOP1 (Table 3). The NPA was high in all criteria, with the NPA reaching 100% in EWGSOP2 and AWGS 2014. AWGS2019 was highly consistent with the other four criteria except FNIH criteria (Kappa = 0.661–0.802, P < 0.001).
Table 3
Analysis of consistency between AWGS 2019 and other diagnostic criteria
PPA (%)
NPA (%)
Kappa value
P value
EWGSOP2
62.1
100
0.749
< 0.001*
AWGS 2014
69.0
100
0.802
< 0.001*
EWGSOP1
83.9
94.6
0.661
< 0.001*
IWGS
70.1
97.2
0.673
< 0.001*
FNIH
21.8
99.6
0.321
< 0.001*
PPA positive predictive value, NPA negative predictive value, AWGS Asian Working Group for Sarcopenia, EWGSOP European Working Group on Sarcopenia in Older People, IWGS the International Working Group on Sarcopenia, FNIH the Foundation for the National Institutes of Health
*P < 0.001
Prevalence of LMM, LMS and LPF
The cut-off values of LMM, LMS and LPF were slightly different under different diagnostic criteria (Table 1). The SMI cut-off value under EWGSOP1 and FNIH criteria was 0.23 kg/m2 higher than that of other criteria, and the prevalence of LMM was increased from 17 to 29% (Table 4). EWGSOP2 reduced the cut-off value of grip strength from 30 kg to 27 kg, reduced the prevalence of LMS by 7.6%, and reduced the prevalence of sarcopenia by 6.8%. Meanwhile, after AWGS2019 update, the critical value of grip strength was increased by 2 kg, and the cut-off value of gait speed was also increased by 0.2 m/s. The results showed that the incidence of LMS, LPF and sarcopenia increased by 4.5%, 8.5%, and 2.7%, respectively (Table 4).
Table 4
Prevalence of LMM, LMS and LPF under different diagnostic criteria
LMM
LMS
LPF
Sarcopenia
AWGS 2019
172 (17.0%)
145 (14.4%)
160 (15.9%)
87 (8.6%)
EWGSOP 2
172 (17.0%)
121 (12%)
75 (7.4%)
54 (5.4%)
AWGS 2014
172 (17.0%)
100 (9.9%)
75 (7.4%)
60 (5.9%)
EWGSOP 1
293 (29.0%)
198 (19.6%)
75 (7.4%)
123 (12.2%)
IWGS
293 (29.0%)
–
160 (15.9%)
87 (8.6%)
FNIH
198 (19.6%)
100 (9.9%)
75 (7.4%)
23 (2.3%)
χ2
105.72
58.02
103.86
88.15
P value
< 0.001*
< 0.001*
< 0.001*
< 0.001*
LMM low muscle mass, LMS low muscle strength, LPF low physical function, AWGS Asian Working Group for Sarcopenia, EWGSOP European Working Group on Sarcopenia in Older People, IWGS the International Working Group on Sarcopenia, FNIH the Foundation for the National Institutes of Health
*P < 0.05
Age-related changes of muscle mass, muscle strength and physical function
LMM, LMS and LPF were defined by AWGS2019 criteria. With the increase of age, the prevalence of LMM, LMS and LPF gradually increased (Fig. 2). The total prevalence of LMM was 17%, which was higher than that of LMS (14.4%) and that of the LPF (15.9%). The prevalence of LMM, LMS and LPF in the group over 80 years old were respectively 35.9, 39.1 and 46.4%. Muscle strength (β = − 0.004, P < 0.001) and physical function (β = − 0.02, P < 0.001) decreased faster with age than muscle mass (β = − 0.004, P < 0.001) (Fig. 3).
Fig. 2
Prevalence of LMM, LMS, and LPF in different age groups. Muscle mass, muscle strength and physical function were assessed by SMI, grip strength, and gait speed, respectively. LMM: low muscle mass; LMS: low muscle strength; LPF: low physical function
Fig. 3
Changes of muscle mass, muscle strength and physical function with age. A and B show that muscle mass (assessed by SMI) is not in parallel with muscle strength (assessed by grip strength) and function (assessed by gait speed), and the decline of muscle strength and function is more significant than the decline of muscle mass. C shows that muscle strength is in parallel with the decline of function. MM: muscle mass; MS: muscle strength; PF: physical function
×
×
Discussion
At present, a number of international sarcopenia working groups have issued expert consensus and diagnostic criteria. The diagnostic criteria are also constantly being updated and improved. We compared the latest criteria of the AWGS2019 with other diagnostic criteria in this study, and found that the incidence of sarcopenia under different criteria varied from 2.3 to 12.2%, with the highest prevalence diagnosed by EWGSOP1 criteria and the lowest prevalence diagnosed by FNIH. Our results is accordance with the prevalence of sarcopenia reported by current studies (8–50%) [15]. One of the main reasons may be that the diagnostic criteria for sarcopenia are inconsistent. A recent study in South Korea investigated 2313 community old adults people aged 70–84, and found that the prevalence of sarcopenia was 1.5–21% [16], slightly higher than this study. The average age of the subjects was also higher than that in our study. Another study in China compared AWGS2019 with other diagnostic criteria and found significant difference in prevalence, ranging from 18.1% in FNIH criteria to 57.1% in EWGSOP1 criteria [17]. The higher prevalence may be due to the fact that most of the study subjects lived in poor villages in Western China and the medical resources were inadequate. They found that the prevalence of sarcopenia diagnosed by EWGSOP2 was 6.5%, significantly lower than EWGSOP1, AWGS 2014, and IWGS (22.3%, 10.9%, 24.5%), but higher than FNIH (6.0%) [18], which was consistent with the results of this study.
Anzeige
We found that AWGS 2019 was highly consistent with other criteria except FNIH for the diagnosis of sarcopenia, with Kappa values as high as 0.802 and 0.749 in AWGS 2014 and EWGSOP 2, respectively. The diagnostic consistency between AWGS 2019 and FNIH was the worst, possibly because the diagnostic criteria of FNIH for sarcopenia were more stringent, requiring simultaneous reduction of muscle mass, grip strength and physical function, while the cut-off values of the two diagnostic criteria were significantly different. Previous studies compared EWGSOP 2 criteria with AWGS, EWGSOP 1, IWGS and FNIH, respectively, in the old adults in the Chinese community, which showed that EWGSOP 2 was not consistent with other criteria in the diagnosis of sarcopenia (Kappa value = 0.159–0.592). The consistency with IWGS criteria is the worst [18]. This study showed that AWGS 2019 had good diagnostic consistency in our study population. However, because the AWGS 2019 criteria were newly revised, further studies are needed for verification and improvement.
The revision of diagnostic criteria mainly lies in the adjustment of cut-off value, and the main reason for the difference in prevalence is the change of cut-off value. Therefore, the analysis of the influence of cut-off value change on the prevalence of sarcopenia can provide a scientific basis for the diagnosis of sarcopenia suitable for the old adults in China in the future. In the new AWGS 2019, the original threshold for SMI (< 7.0 kg/cm2) was retained, but the cut-off value for male grip strength was increased from < 26 kg to < 28 kg. There has been evidence that the prevalence of LMS in male sarcopenia patients was higher (22.1%) when the cut-off value of grip strength < 28 kg, compared with when the cut-off value < 26 kg (12.9%) [16]. In this study, when the cut-off value increased from 26 kg to 27 kg, 28 kg and 30 kg, the prevalence of LMS increased by 2.1%, 2.4% and 5.2%, respectively. Therefore, these differences in male prevalence may be related to different diagnostic cut-off values for grip strength. In addition, in AWGS 2019, the cut-off value of LPF increased from≤0.8 m/s to < 1 m/s, and the prevalence of LPF can be increased from 5.7 to 23.6% [16], which is similar to the results of this study. If the cut-off value of gait speed is increased by 0.2 m/s, the prevalence could be increased by 8.5%. Therefore, slight adjustment of the cut-off value can significantly affect the diagnosis of sarcopenia. Due to regional, ethnic and national differences, the cut-off values developed by various working groups may be not applicable for Chinese elder individuals. Therefore, it is particularly important to identity the cut-off values suitable for the diagnosis of sarcopenia in China, which is also the focus of our future research.
With age, muscle strength and function declined faster than muscle mass. Under 80 years of age, muscle mass decreased more, while muscle strength and function began to decline rapidly over 80 years of age. Skeletal muscle is used to maintain energy consumption when other sources of energy are depleted, so reduced muscle mass can significantly increase morbidity and mortality from otherwise survivable diseases [19]. The old adults with LPF and LMS are more vulnerable to become disability and frailty. When they face mild stress (such as replacement of drugs, minimally invasive surgery, etc.), they are more likely to stay in bed, which may induce acute onset of chronic diseases, or increase the hospitalization rate and mortality, thus leading to further deterioration of muscle strength and function, and resulting in a vicious cycle [20‐22]. Therefore, early targeted intervention measures should be given to the old adults with different ages and physical functions to prevent the occurrence and development of sarcopenia.
Another result of this study indirectly confirmed that functional decline was more significant in the old adults. Compared with EWGSOP1, which had the highest prevalence of sarcopenia, IWGS increased the functional cut-off value (gait speed < 1 m/s vs ≤0.8 m/s) and maintained the same muscle mass cut-off value (SMI < 7.23 kg/m2), but the diagnostic prevalence was still lower in the old adults under 80 years old, even lower than AWGS2019 criteria (SMI < 7.0 kg/m2). This may be because muscle mass loss is more common in old adults under 80 years old, while the prevalence of sarcopenia is relatively low even with increased diagnostic cut-off values for low physical function. However, when the gait speed of the old adults decreased significantly after 80 years old, the prevalence of IWGS began to increase significantly, which was almost consistent with the prevalence of EWGSOP1.
Anzeige
Conclusions
In this study, it was found that the decline of muscle strength and function was more obvious than that of muscle mass in the elder male population. Before the age of 80, the change of muscle mass should be closely monitored to avoid the reduction of muscle mass. After the age of 80, more attention should be paid to functional improvement to prevent disability. It suggests that we should provide targeted preventive intervention measures for different ages and functional states of the old adults in clinical practice.
Acknowledgements
Not applicable.
Declarations
Ethics approval and consent to participate
The study was conducted in accordance with the principles of the Declaration of Helsinki. The research proposal was approved by the Ethics Committee and the Institutional Review Committee of Hospital (Approval Number: S2019–140-01). Informed consent was obtained from each patient.
Consent for publication
Not applicable.
Anzeige
Competing interests
The authors declare that they have no conflicts of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Prevalence of sarcopenia under different diagnostic criteria and the changes in muscle mass, muscle strength, and physical function with age in Chinese old adults
verfasst von
Mengyu Cao Junsong Lian Xisheng Lin Jinwei Liu Chao Chen Shuaixuan Xu Shuang Ma Fang Wang Nihui Zhang Xiaolei Qi Guogang Xu Nan Peng
Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.
Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.
Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.
Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
